Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Sonnet Biotherapeutics Holdings

13/02/2025 23:09

* Sonnet Biotherapeutics Holdings Inc  SONN.OQ  reported a
quarterly adjusted loss of $1.56​​ per share for the quarter
ended December 31, higher than the same quarter last year, when
the company reported EPS of $-2.48.  The lone analyst forecast
for the quarter was for a loss of $1.39 per share. 
    * Revenue rose 5,267.7% to $1.00 million from a year ago;
analysts
expected zero. 
    * Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was a loss of $1.56​.
    * Sonnet Biotherapeutics Holdings Inc shares had risen
by 6.8%
this quarter.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $20.00 
This summary was machine generated from LSEG data February 13 at
11:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -1.39          -1.56          Missed
 Sep. 30 2024      -5.52          -3.83          Beat
 Jun. 30 2024      -6.12          -5.60          Beat
 Mar. 31 2024      1.08           0.56           Missed